profit from every $100 of sales.
$0$100
Bicycle Therapeutics
$3.45-6.50% today
-47.4% in 1 year
1-year low $3.381-year high $7.52
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Bicycle Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $14.5 million in 2022 to $72.6 million in 2025, with -$219 million of profit last year.
SalesProfit
Bicycle Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Bicycle Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Bicycle Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 14 | 27 | 35 | 73 | |
| – | – | – | – | |
| -117 | -190 | -209 | -248 | |
| -107 | -169 | -165 | -212 | |
| -113 | -181 | -169 | -219 | |
| -3.80 | -5.08 | -2.90 | -3.16 | |
| – | – | – | – | |
| -806.6% | -704.1% | -592.9% | -341.3% | |
| -779.3% | -669.7% | -479.2% | -301.7% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 411 | 595 | 957 | 718 |
| Cash | 339 | 526 | 880 | 628 |
| Total debt | 44 | 45 | 9 | 17 |
| Total liabilities | 140 | 224 | 164 | 108 |
| 271 | 371 | 793 | 610 | |
| 30 | 36 | 58 | 69 | |
| -27.8% | -33.4% | -16.9% | -27.6% | |
| -41.6% | -48.7% | -21.3% | -35.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -86 | -61 | -165 | -250 | |
| 19 | 3 | 1 | 2 | |
| -105 | -64 | -166 | -252 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 27 | 32 | 38 | 39 |
Valuation
- –
- –
- –
- 0.5×
- 3.3×
- –
- –
- -104.2%
- -90.5%
- 0.0%
Profitability
- -11.9%
- -341.3%
- -301.7%
- -333.1%
- -40.2%
- -30.5%
- -35.7%
- -33.6%
- -40.2%
- 362.4%
Growth
- +71.2%
- –
- −52.2%
- –
- +28.9%
Financial health
- -2.9×
- 0.03
- 2.1%
- -1,194.1×
- 12.66
- 12.66
- 0.10
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 11%of 952
Top 8%of 870
What analysts expect
- Average price target
- $10.67
- Range
- $8.00 – $12.00
- 4 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 30, 2026 | -0.87 | -0.58 | −51.0% |
| Mar 17, 2026 | -0.29 | -0.94 | +69.1% |
| Oct 30, 2025 | -0.85 | -1.09 | +22.0% |
| Aug 8, 2025 | -1.14 | -0.95 | −20.0% |
| May 1, 2025 | -0.88 | -0.86 | −2.3% |
| Feb 25, 2025 | -0.80 | -0.85 | +5.9% |
| Oct 31, 2024 | -0.74 | -0.78 | +5.1% |
| Aug 6, 2024 | -0.77 | -1.10 | +30.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
37No pass
Benjamin Graham
73Pass
Philip Fisher
39No pass
Peter Lynch
71Pass
Joel Greenblatt
0No pass
Charlie Munger
31No pass
Terry Smith
40No pass
Questions about Bicycle Therapeutics
Is Bicycle Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Bicycle Therapeutics AI analysis
What does Bicycle Therapeutics do?
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. It is in Biotechnology.
Does Bicycle Therapeutics pay a dividend?
No. Bicycle Therapeutics does not pay a dividend at the moment.
Is Bicycle Therapeutics stock halal?
No. Bicycle Therapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 260% of its market value, at or above the 33% limit. How we check
How has Bicycle Therapeutics stock done over the past year?
Down 47.4% over the past twelve months, to $3.45. It traded between $3.38 and $7.52 and is 54.1% below its high.
Who are Bicycle Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Bicycle Therapeutics's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.